Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD81 | P60033 | 2/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965467 | 1.00 | CD81 (0.46) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL6561035 | 1.00 | CD81 (0.46) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL6561197 | 1.00 | CD81 (0.46) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL1348823 | 1.00 | CD81 (0.46) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL6121809 | 0.90 | APLNR (0.42) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL6382497 | 0.90 | APLNR (0.42) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL12914998 | 0.90 | CD81 (0.39) | CD81MEN1KMT2A | |
| SCHEMBL15352277 | 0.90 | APLNR (0.42) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL21800873 | 0.90 | APLNR (0.42) | CD81APLNRSLC1A2SLC1A1SLC6A4 | |
| SCHEMBL10046563 | 0.77 | CD81 (0.37) | CD81APLNRSLC1A2SLC1A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3882239-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-9290490-B2 | Aminopyrimidines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| EP-2454270-B1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2015-02-11 | — | — | EP | disclosed |
| EP-2454270-B1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2015-02-11 | — | — | EP | disclosed |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-05-29 | — | — | US | disclosed |
| WO-2013160810-A2 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2013-10-31 | — | — | WO | disclosed |
| WO-2011080562-A1 | NOVEL AZA-PEPTIDES CONTAINING 2,2-DISUBSTITUTED CYCLOBUTYL AND/OR SUBSTITUTED ALKOXY BENZYL DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011007230-A2 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
| EP-1144365-B1 | INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | CD81 2758/4885APLNR 4637/4885SLC1A2 4039/4885 |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | CD81 2062/4885APLNR 3162/4885SLC1A2 4703/4885 |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | CD81 1889/4885APLNR 4085/4885SLC1A2 3045/4885 |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | CD81 1199/4885APLNR 3302/4885SLC1A2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.